Nadia Harbeck

Summary

Affiliation: University of Cologne
Country: Germany

Publications

  1. pmc Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel
    Eva J Kantelhardt
    Klinik und Poliklinik für Gynäkologie, Martin Luther Universitat, Halle Saale, Germany
    BMC Cancer 11:140. 2011
  2. pmc CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients
    Dimo Dietrich
    Epigenomics AG, Berlin, Germany
    BMC Cancer 10:247. 2010
  3. doi request reprint Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy
    N Harbeck
    Department of Oncology, Breast Center, Department of Obstetrics and Gynecology, University of Cologne, Cologne, Germany
    Ann Oncol 22:1250-8. 2011
  4. doi request reprint A new look at node-negative breast cancer
    Nadia Harbeck
    Breast Center, University of Cologne, Cologne, Germany
    Oncologist 16:51-60. 2011
  5. doi request reprint A new look at node-negative breast cancer
    Nadia Harbeck
    Breast Center, University of Cologne, Cologne, Germany
    Oncologist 15:29-38. 2010
  6. doi request reprint Personalized treatment of early-stage breast cancer: present concepts and future directions
    Nadia Harbeck
    Breast Center, Department of Gynecology and Obstetrics, University Hospital Köln, Cologne, Germany
    Cancer Treat Rev 36:584-94. 2010
  7. ncbi request reprint Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer
    Nadia Harbeck
    Department of Obstetrics and Gynecology, Technical University of Munich, Germany
    Clin Breast Cancer 5:348-52. 2004
  8. ncbi request reprint Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients
    Julia Dorn
    Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
    Clin Cancer Res 13:1742-8. 2007
  9. doi request reprint Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study
    Volker Moebus
    Department of Gynecology and Obstetrics, Klinikum Frankfurt Hoechst, Academic Hospital of Goethe University Frankfurt, Gotenstrasse 6 8, D 65929, Frankfurt, Germany
    J Clin Oncol 28:2874-80. 2010
  10. ncbi request reprint Side-effects of pre-operative epirubicin-paclitaxel therapy in primary breast cancer associated with tumor biology
    Mathias Warm
    Department of Senology, University of Cologne, Cologne, Germany
    Anticancer Res 29:2675-80. 2009

Collaborators

Detail Information

Publications36

  1. pmc Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel
    Eva J Kantelhardt
    Klinik und Poliklinik für Gynäkologie, Martin Luther Universitat, Halle Saale, Germany
    BMC Cancer 11:140. 2011
    ..High-risk node-negative patients should receive chemotherapy. Anthracycline-based regimens are accepted as a standard, the additional benefit of taxanes remains an open question...
  2. pmc CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients
    Dimo Dietrich
    Epigenomics AG, Berlin, Germany
    BMC Cancer 10:247. 2010
    ..In this study, the DNA methylation status of 202 candidate loci was screened to identify those loci that may predict outcome in LNP/estrogen receptor-positive (ER+) breast cancer patients with adjuvant anthracycline-based chemotherapy...
  3. doi request reprint Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy
    N Harbeck
    Department of Oncology, Breast Center, Department of Obstetrics and Gynecology, University of Cologne, Cologne, Germany
    Ann Oncol 22:1250-8. 2011
    ..Since adjuvant therapy for BC is potentially curative, emphasis must be placed on finding treatments combining maximum efficacy with the minimum of long-term side-effects in order to achieve survival with preserved quality of life...
  4. doi request reprint A new look at node-negative breast cancer
    Nadia Harbeck
    Breast Center, University of Cologne, Cologne, Germany
    Oncologist 16:51-60. 2011
    ..Node-negative breast cancer does not automatically suggest a good prognosis, or the preclusion of chemotherapy benefits, and additional biomarkers are needed to help identify patients who do benefit from chemotherapy...
  5. doi request reprint A new look at node-negative breast cancer
    Nadia Harbeck
    Breast Center, University of Cologne, Cologne, Germany
    Oncologist 15:29-38. 2010
    ..Node-negative breast cancer does not automatically suggest a good prognosis, or the preclusion of chemotherapy benefits, and additional biomarkers are needed to help identify patients who do benefit from chemotherapy...
  6. doi request reprint Personalized treatment of early-stage breast cancer: present concepts and future directions
    Nadia Harbeck
    Breast Center, Department of Gynecology and Obstetrics, University Hospital Köln, Cologne, Germany
    Cancer Treat Rev 36:584-94. 2010
    ..It will also highlight how carefully molecular tests need to be methodologically and clinically validated before they can be applied for clinical decision making...
  7. ncbi request reprint Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer
    Nadia Harbeck
    Department of Obstetrics and Gynecology, Technical University of Munich, Germany
    Clin Breast Cancer 5:348-52. 2004
    ....
  8. ncbi request reprint Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients
    Julia Dorn
    Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
    Clin Cancer Res 13:1742-8. 2007
    ....
  9. doi request reprint Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study
    Volker Moebus
    Department of Gynecology and Obstetrics, Klinikum Frankfurt Hoechst, Academic Hospital of Goethe University Frankfurt, Gotenstrasse 6 8, D 65929, Frankfurt, Germany
    J Clin Oncol 28:2874-80. 2010
    ..We compared intense dose-dense (IDD) adjuvant chemotherapy with conventionally scheduled adjuvant chemotherapy in patients with high-risk primary breast cancer...
  10. ncbi request reprint Side-effects of pre-operative epirubicin-paclitaxel therapy in primary breast cancer associated with tumor biology
    Mathias Warm
    Department of Senology, University of Cologne, Cologne, Germany
    Anticancer Res 29:2675-80. 2009
    ..The objective of this analysis is to identify relationships between side-effects, tumor biological factors and response to pre-operative epirubicin and paclitaxel therapy in primary breast cancer...
  11. ncbi request reprint Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424)
    Nadia Harbeck
    Department of Obstetrics and Gynecology, Technical University, D 81675 Munich, Germany
    Cancer Res 62:4617-22. 2002
    ....
  12. ncbi request reprint Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts
    Nadia Harbeck
    Department of Obstetrics and Gynecology, Technical University of Munich, Munich, Germany
    Clin Breast Cancer 3:196-200. 2002
    ..Thus, combined determination of the invasion factors uPA and PAI-1 supports risk-adapted individualized therapeutic strategies in patients with primary breast cancer, particularly in those with node-negative breast cancer...
  13. ncbi request reprint 3D breast ultrasound: a significant predictor in breast cancer reduction under pre-operative chemotherapy
    Mathias Warm
    Department of Senology, University of Cologne, Cologne, Germany
    Anticancer Res 31:4039-42. 2011
    ..The objective was the investigation of a possible predictive quantitative impact of initial tumor sphericity, measured by 3D sonography, on response to pre-operative chemotherapy...
  14. ncbi request reprint Improvement of safety profile of docetaxel by weekly administration in patients with metastatic breast cancer
    Mathias Warm
    Department of Senology, University of Cologne, Germany
    Onkologie 30:436-41. 2007
    ..This is a retrospective cohort study on the safety and efficacy profiles of weekly docetaxel at varying doses in patients with pretreated metastatic breast cancer...
  15. pmc Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials
    Sibylle Loibl
    Department of Obstetrics and Gynecology, German Breast Group, Neu Isenburg, Germany
    Breast Cancer Res 10:R77. 2008
    ..Furthermore, most physicians tend towards therapy regimens without the use of dose-dense, highly active taxane-based treatments because of a lack of data regarding toxicities of these compounds in older patients...
  16. ncbi request reprint Impact of tumor biological factors on response to pre-operative epirubicin and paclitaxel chemotherapy in primary breast cancer
    Mathias Warm
    Department of Senology, University of Cologne, Germany
    Anticancer Res 27:1031-8. 2007
    ....
  17. doi request reprint Benefits of early and prolonged fulvestrant treatment in 848 postmenopausal advanced breast cancer patients
    Mathias Warm
    Breast Center, University of Cologne, Kerpener Strasse 62, 50924 Cologne, Germany
    Breast Cancer Res Treat 125:127-36. 2011
    ....
  18. ncbi request reprint Tumor-associated proteolytic factors uPA and PAI-1: critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithms
    Nadia Harbeck
    Department of Obstetrics and Gynecology, Technical University of Munich, Munich, Germany
    Crit Rev Clin Lab Sci 44:179-201. 2007
    ..This concept could be useful in assessing and maximizing the performance of risk assessment and the quality of therapeutic indications...
  19. ncbi request reprint Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer
    Nadia Harbeck
    Department of Obstetrics and Gynecology, Technical University of Munich, Germany
    Thromb Haemost 91:450-6. 2004
    ....
  20. ncbi request reprint Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma
    Julia Dorn
    Clinical Research Unit, Department of Obstetrics and Gynecology, Technical University of Munich, D 81675 Munich, Germany, and Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada
    Biol Chem 387:1121-8. 2006
    ..These results support the notion that several tissue kallikreins are co-expressed in ovarian cancer patients, substantiating the existence of a steroid hormone-driven tissue kallikrein cascade in this disease...
  21. doi request reprint Health-related quality of life in male breast cancer patients
    Christoph Kowalski
    Institute for Medical Sociology, Health Services Research and Rehabilitation Science, Faculty of Human Science and Faculty of Medicine, University of Cologne, Cologne, Germany
    Breast Cancer Res Treat 133:753-7. 2012
    ..Future research needs to assess HRQoL with cancer-specific questionnaires and longitudinal designs also focussing on male patients in breast centres...
  22. doi request reprint Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy
    Oleg Gluz
    Breast Center, University of Cologne, Kerpener Strasse 34, 50931 Cologne, Germany
    J Clin Oncol 27:6144-51. 2009
    ....
  23. ncbi request reprint FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer
    Christoph Thussbas
    Department of Obstetrics and Gynecology, Institute of Pathology, and Institute for Medical Statistics and Epidemiology, Technical University of Munich, Munich, Germany
    J Clin Oncol 24:3747-55. 2006
    ..5 months)...
  24. doi request reprint Postoperative sense of well-being and quality of life in breast cancer patients do not depend on type of primary surgery
    Mathias Warm
    Department of Senology, University of Cologne, Germany
    Onkologie 31:99-104. 2008
    ..3 types of surgery are compared: breast-conserving surgery; modified radical mastectomy with or without primary reconstruction...
  25. ncbi request reprint Antibody therapy for breast cancer
    Amina Willems
    Department of Obstetrics and Gynecology, Technical University of Munich, Germany
    Anticancer Res 25:1483-9. 2005
    ..It binds to a different epitope on HER2/neu than trastuzumab and inhibits heterodimerization with other HER receptors. Phase I data showed that 2C4 is well tolerated and clinically active...
  26. ncbi request reprint European Organisation for Research and Treatment of Cancer (EORTC) Pathobiology Group standard operating procedure for the preparation of human tumour tissue extracts suited for the quantitative analysis of tissue-associated biomarkers
    Manfred Schmitt
    Clinical Research Unit, Department of Obstetrics and Gynecology, Technical University of Munich, Germany
    Eur J Cancer 43:835-44. 2007
    ..The resulting tissue cell debris sediment is a rich source of genomic DNA...
  27. doi request reprint Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker
    Ariane Sadr-Nabavi
    Department of Obstetrics and Gynecology, Technische Universitaet Muenchen, Munich, Germany
    Int J Cancer 124:1727-35. 2009
    ..Furthermore, these data point towards a possible predictive impact of EFEMP1 expression in primary breast cancer...
  28. doi request reprint A retrospective investigation of women's experience with breast reconstruction after mastectomy
    Nina Ditsch
    Department of Obstetrics and Gynaecology, Breast Center, Ludwig Maximilians University, Campus Grosshadern, Marchioninistr 15, 81377 Munich, Germany
    Arch Gynecol Obstet 287:555-61. 2013
    ..Hence, many patients opt for reconstructive surgery. This study evaluated the effects of different types of reconstructive surgery after mastectomy on the functional and psychological adjustment of patients...
  29. ncbi request reprint Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination
    Nadia Harbeck
    Clinical Research Group, Department of Obstetrics and Gynecology, Technical University of Munich, Munich, Germany
    J Clin Oncol 20:1000-7. 2002
    ..The improvement in clinical risk assessment gained by combining these factors is evaluated here...
  30. ncbi request reprint Optimized pro-active management of anemia by Epoetin alpha in pre-operative chemotherapy for primary breast cancer
    Mathias Warm
    Department of Senology, University of Kologne, Germany
    Oncol Rep 21:777-85. 2009
    ....
  31. ncbi request reprint Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: tasks of the Receptor and Biomarker Group of the European Organization for Research and T
    Manfred Schmitt
    Clinical Research Unit, Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universitaet Muenchen, Ismaninger Strasse 22, D 81675 Munich, Germany
    Int J Oncol 25:1397-406. 2004
    ..With this approach, a major step forward in the knowledge and understanding of the biological role and the clinical utility of tumor-associated biomarkers would be anticipated...
  32. ncbi request reprint Immunohistochemical demonstration of the zinc metalloprotease insulin-degrading enzyme in normal and malignant human breast: correlation with tissue insulin levels
    Razvan T Radulescu
    Clinical Research Unit, Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str 22, D 81675 Munchen, Germany
    Int J Oncol 30:73-80. 2007
    ..Our present report should also provide an experimental starting point towards exploring a potential role of IDE in the control of tumor progression...
  33. doi request reprint Associations between hospital and patient characteristics and breast cancer patients' satisfaction with nursing staff
    Christoph Kowalski
    Institute for Medical Sociology, Health Services Research and Rehabilitation Science, Faculty of Human Science and Faculty of Medicine, University of Cologne, Germany
    Cancer Nurs 35:221-8. 2012
    ..Only a few studies have investigated the association between hospital characteristics and breast cancer patients' satisfaction with nursing staff...
  34. doi request reprint Angiogenesis inhibitors in the management of breast cancer
    Verena Bossung
    Breast Center, Department of Obstetrics and Gynecology, University Hospital of Cologne, Cologne, Germany
    Curr Opin Obstet Gynecol 22:79-86. 2010
    ..This review highlights therapeutic agents from recent breast cancer trials showing the greatest potential for further clinical use in the near future...
  35. ncbi request reprint Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals
    Katharina Seck
    Department of Obstetrics and Gynecology, Technical University of Munich, Munich, Germany
    Clin Cancer Res 11:5886-92. 2005
    ..The intention of this population study is to assess and to evaluate gene variations in the entire coding region of the dihydropyrimidine dehydrogenase gene (DPYD), which could be implicated in DPD malfunction...
  36. doi request reprint Optimal sequencing of anti-HER2 therapy throughout the continuum of HER2-positive breast cancer: evidence and clinical considerations
    Nadia Harbeck
    Breast Center, Department of Gynecology and Obstetrics, University of Munich, Campus Großhadern, Marchioninistr 15, 81377, Munich, Germany
    Drugs 73:1665-80. 2013
    ..This article will provide evidence-based guidance for sequencing anti-HER2 therapy throughout the continuum of breast cancer therapy. ..